Novocure Ltd. (NVCR) News
Filter NVCR News Items
NVCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVCR News Highlights
- NVCR's 30 day story count now stands at 7.
- Over the past 28 days, the trend for NVCR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ROOT, NOV and TOP are the most mentioned tickers in articles about NVCR.
Latest NVCR News From Around the Web
Below are the latest news stories about NOVOCURE LTD that investors may wish to consider to help them evaluate NVCR as an investment opportunity.
15 Best Falling Stocks To Buy NowIn this piece, we will take a look at the 15 best falling stocks to buy now. If you want to skip our overview of the current stock market environment and our coverage of the latest stock market news, then you can skip ahead to 5 Best Falling Stocks To Buy Now. With 2023 coming […] |
The Top and Bottom Stocks of 2023Top performing stocks in 2023 included those in the technology sector, taking advantage of developments in AI. The bottom performers included NVCR, which was punished because of its ovarian cancer trials' failure to improve survival rates in patients. |
Evercore ISI Is Pounding the Table on Rivian (RIVN) Stock With Outperform RatingRivian stock is getting a boost on Tuesday after analysts at Evercore ISI weighed in on RIVN shares with a reiterated outperform rating. |
FCEL Stock Alert: FuelCell Energy Announces AI Deal With IBMFuelCell Energy stock is climbing higher on Tuesday as investors in FCEL celebrate the company signing a deal with IBM! |
Novocure Layoffs 2023: What to Know About the Latest NVCR Job CutsNovocure layoffs are coming for 13% of the company's workers as it seeks to reduce its headcount by 200 people to reduce costs. |
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to ProfitabilityROOT, Switzerland, November 28, 2023--Novocure today announced a series of actions to strengthen and optimize business operations to support growth drivers and long-term value creation. |
Novocure to Participate in 35th Annual Piper Sandler Healthcare ConferenceROOT, Switzerland, November 21, 2023--Novocure announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. |
NovoCure Limited (NASDAQ:NVCR) institutional owners may be pleased with recent gains after 85% loss over the past yearKey Insights Given the large stake in the stock by institutions, NovoCure's stock price might be vulnerable to their... |
11 Best Undervalued UK Stocks To Buy NowIn this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now. If you want to skip our overview of the British economy, then take a look at 5 Best Undervalued UK Stocks To Buy Now. The U.K. is one of the biggest economies in the world and a […] |
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual MeetingROOT, Switzerland, November 10, 2023--Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting from Nov. 16 to Nov. 19 in Vancouver, Canada. |